Article Figures & Data
Figures
- Figure 1.
FLX is oncolytic in multiple cancers. Dose response curve of FLX in U87, Panc1 and HT29 cells. Data are presented as mean±SEM of 3-5 independent experiments performed in quadruplicate. ANOVA, p<0.001, followed by t-test where **p<0.01, ***p<0.001, compared to vehicle-treated control.
- Figure 2.
CX614 is oncolytic in multiple cancers. Dose response curve of CX614 in U87, Panc1 and HT29 cells. Data are presented as mean±SEM of 3-4 independent experiments performed in quadruplicate. ANOVA, p<0.01, followed by t-test where *p<0.05, **p<0.01, compared to vehicle-treated control.
- Figure 3.
CX614 enhances FLX's oncolytic effects. FLX and CX614 synergistically reduce A) U87, B) Panc1 and C) HT29 cell viability. Data are presented as mean±SEM of 3-4 independent experiments performed in quadruplicate. T-test where *p<0.05, **p<0.01, compared to vehicle-treated control. #p<0.05, king's synergy test, demonstrating significant synergistic interaction.
